OpenEvidence has announced its acquisition of Amaro, an AI-driven advertising startup founded by Kush Khosla and Sauren Khosla, with backing from Google Ventures and Greycroft. Amaro’s technology is designed to help organizations optimize advertising campaigns across the entire deployment chain, leveraging rapid, intelligent automation at scale. The acquisition strengthens OpenEvidence’s commitment to expanding its platform for healthcare professionals, building modern and user-centric advertising infrastructure informed by Amaro’s team and expertise.
The synergy of these two companies has drawn praise from investors, including GV general partner Sangeen Zeb, who stated, “The Khosla brothers have built an exceptional team at Amaro combining resilience, vision, and technical excellence. This acquisition is a great fit, as Amaro’s team and technology will help OpenEvidence accelerate its growth and further expand access to a trusted tool for clinicians.” OpenEvidence, a fast-growing clinical decision support and medical search platform, now integrates Amaro’s automation to further accelerate platform innovation and deliver enhanced advertising capabilities for clinicians at the point of care.
Marketing Technology Insights: Measured Appoints Mike Finnell as SVP of Marketing and Andy Dubickas as VP of Strategic Partnerships
OpenEvidence cofounder Zachary Ziegler underscored the alignment of visions, noting that the Amaro team’s speed, persistence, and dedication to quality would give OpenEvidence a substantial boost as it scales. He highlighted the company’s free-to-physician, ad-supported model, which powers over half a million clinical inquiries each day and is used by more than 40% of practicing U.S. physicians. In fact, the platform continues to add roughly 90,000 new clinicians each month, following its recent $210 million Series B financing at a $3.5 billion valuation. The acquisition of Amaro amplifies OpenEvidence’s efforts to centralize trusted, high-quality information for clinicians and patients, ensuring that effective AI tools remain accessible regardless of a practice’s resources.
Marketing Technology Insights: AgentVine Debuts Public Beta as First Ad Network for AI Agents
Ultimately, this acquisition signals OpenEvidence’s surging momentum and its focus on combining leading-edge automation with deep healthcare expertise to reshape how clinical decisions are informed in the United States.
Marketing Technology Insights: Eulerity Powers National Brands via Google TV Integration
For media inquiries, you can write to our MarTech Newsroom at sudipto@intentamplify.com
